器官细胞pH值作为一种新兴的脆弱性,在癌症中被利用
Cheska Marie Galapate1, Cosimo Commisso1
1Cancer Metabolism and Microenvironment Program, National Cancer Institute (NCI)-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, 10901 North Torrey Pines Road La Jolla, CA 92037, USA.
Trends in cancer
|October 24, 2025
概括
癌细胞通过管理酸性副产品来维持性细胞内pH (pHi),从而促进瘤生长和存活. 向器官酸性化是一个潜在的治疗策略来对抗癌症.
科学领域:
- 生物化学 生物化学
- 细胞生物学 细胞生物学
- 在瘤学瘤学.
背景情况:
- 癌细胞表现出代谢重编程,有利于糖解并产生酸性副产品.
- 质子的积累降低了细胞内pH值 (pHi),癌细胞可以抵消这种作用.
- 性pHi赋予了生存优势,促进了癌症的增殖,迁移和抵抗细胞死亡.
研究的目的:
- 探索癌细胞pH稳态机制,重点关注器官 pH.
- 为了研究细胞器pH值对瘤进展的影响.
- 评估向癌症中细胞器酸化的治疗潜力.
主要方法:
- 审查控制癌细胞pH稳态的机制.
- 分析器官的pH调节及其在瘤进展中的作用.
- 对向器官酸性化中的关键载体的抑制剂的评估.
主要成果:
- 癌细胞利用膜载体和有机细胞隔离来管理细胞内pH值.
- 器官细胞酸化对于维持支持癌症生存的性pH值至关重要.
- 器官细胞酸化载体的抑制剂显示出治疗的前景.
结论:
- 维持性细胞内pH值对于癌细胞的增殖,迁移和生存至关重要.
- 器官细胞酸性化是维持癌细胞pH恒温的关键过程.
- 向器官酸性化代表了癌症治疗的有前途的治疗脆弱性.
相关概念视频
Adaptive Mechanisms in Cancer Cells
6.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
6.9K
Cancers Originate from Somatic Mutations in a Single Cell
14.5K
Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
14.5K
Induced Pluripotent Stem Cells
5.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
5.4K
Cancer Stem Cells and Tumor Maintenance
5.9K
Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.9K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Metastasis
6.4K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.4K


